Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
| ▸ | GLB1 | P16278 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21660212 | 0.83 | CARM1 (0.34) | PIK3CD | |
| SCHEMBL18389282 | 0.80 | ARG1 (0.37) | — | |
| SCHEMBL18082542 | 0.80 | BCHE (0.42) | — | |
| SCHEMBL10076884 | 0.80 | BCHE (0.42) | — | |
| SCHEMBL10150975 | 0.78 | PIK3CD (0.50) | PIK3CD | |
| SCHEMBL17681022 | 0.77 | — | — | |
| SCHEMBL12280928 | 0.77 | GBA1 (0.30) | GBA1 | |
| SCHEMBL27013138 | 0.76 | GBA1 (0.34) | GBA1SORT1GLB1PIK3CD | |
| SCHEMBL13171586 | 0.75 | GBA1 (0.40) | GBA1SORT1PIK3CD | |
| SCHEMBL25445185 | 0.73 | SIGMAR1 (0.41) | GBA1SORT1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550071-B2 | PPAR agonists | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-02-04 | — | — | US | disclosed |
| WO-2019031618-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | 大正製薬株式会社 | 2019-02-14 | — | — | WO | disclosed |
| EP-3434668-A1 | INDOLO-SUBSTITUTED-PIPERIDINE COMPOUNDS AS ESTROGEN RECEPTOR DEGRADING AGENT | Luoxin Biotechnology (Shanghai) Co., Ltd. (CN) | 2019-01-30 | — | — | EP | disclosed |
| US-20180170857-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170857-A1 | PPAR AGONISTS | PPARG, PPARD, PPARA | GBA1 1690/4885SORT1 4360/4885GLB1 1573/4885 |
| US-10550071-B2 | PPAR agonists | PPARG, PPARD, PPARA | GBA1 1690/4885SORT1 4360/4885GLB1 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.